• 1. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 2. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 3. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 4. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 5. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles 2,4-disubstituted thiazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Thiazoles 2,4-disubstituted thiazoles

Professional Introduction to 2-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol (CAS No. 333385-00-5)

2-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol, a compound with the chemical identifier CAS No. 333385-00-5, has garnered significant attention in the field of pharmaceutical research due to its unique structural properties and potential biological activities. This compound belongs to the thiazole derivatives, a class of heterocyclic compounds that have been widely studied for their diverse pharmacological effects. The presence of a thiazole ring fused with an ethanol moiety makes this molecule a promising candidate for further investigation in drug discovery and development.

The structural framework of 2-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol consists of a central thiazole ring substituted with a methyl group at the 4-position and an ethanol group at the 2-position. This specific arrangement of functional groups contributes to its distinct chemical and biological properties. The thiazole core is known for its stability and ability to interact with various biological targets, making it a valuable scaffold in medicinal chemistry. The ethanol side chain provides a hydrophilic extension, which can enhance solubility and bioavailability, crucial factors in drug design.

In recent years, there has been growing interest in thiazole derivatives due to their reported antimicrobial, anti-inflammatory, and anticancer activities. Studies have shown that compounds containing the thiazole moiety can modulate multiple cellular pathways, making them effective against a range of diseases. For instance, research has demonstrated that certain thiazole derivatives exhibit inhibitory effects on enzymes such as COX and LOX, which are involved in inflammatory processes. The compound 2-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol is being explored for its potential to interact with similar targets, offering a new avenue for therapeutic intervention.

One of the most compelling aspects of 2-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol is its mechanism of action. Preliminary studies suggest that this compound may exert its effects by binding to specific proteins or enzymes within cells. The interaction with these targets can lead to altered cellular signaling pathways, ultimately resulting in therapeutic benefits. For example, researchers have hypothesized that the thiazole ring may interfere with the activity of certain kinases, which are critical regulators of cell growth and division. Further investigation is needed to fully elucidate the molecular mechanisms underlying the observed biological activities.

The synthesis of 2-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol involves multi-step organic reactions that require precise control over reaction conditions. The process typically begins with the formation of the thiazole ring through cyclization reactions involving sulfur-containing precursors. Subsequent functionalization steps introduce the methyl group and the ethanol side chain at appropriate positions on the ring. Advanced synthetic techniques such as catalytic hydrogenation and nucleophilic substitution have been employed to achieve high yields and purity levels. These synthetic strategies are essential for obtaining sufficient quantities of the compound for further biological testing.

Evaluation of the pharmacokinetic properties of 2-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol is crucial for assessing its potential as a drug candidate. Parameters such as absorption, distribution, metabolism, and excretion (ADME) need to be carefully studied to determine how the compound behaves within an organism. In vitro assays have been used to assess its solubility in different media and its stability under various conditions. Additionally, animal models have been employed to evaluate its bioavailability and metabolic fate. These studies provide valuable insights into how the compound might be processed by the body and whether it meets the criteria for further clinical development.

The toxicological profile of 2-(4-methyl-1,3-thiazol-2-ylylanthanone)-1 is another critical aspect that needs thorough investigation before it can be considered for human use. Acute toxicity studies are conducted to determine safe dosages and identify any immediate adverse effects. Chronic toxicity studies provide long-term data on the compound's effects on various organ systems. These studies are essential for ensuring patient safety if the compound progresses to clinical trials. By adhering to stringent regulatory guidelines, researchers can gather comprehensive toxicological information that supports responsible drug development practices.

The potential therapeutic applications of 2-(4-methylthieno[3][;;]thiophene]-3-carboxylic acid are diverse and exciting. Given its structural similarities to known bioactive compounds, it may find utility in treating conditions such as inflammation-related diseases or cancer. Clinical trials would be necessary to confirm these potential benefits in human populations. Collaborations between academic researchers and pharmaceutical companies could accelerate this process by combining expertise in chemistry, biology, and medicine. Such partnerships are essential for translating laboratory findings into tangible therapeutic solutions.

The future direction of research on 2-(4-methylthieno[3][;;]thiophene)-3-carboxylic acid looks promising as new technologies continue to emerge in drug discovery fields like high-throughput screening (HTS) and computational modeling (in silico). These tools enable researchers to rapidly identify promising candidates from large libraries of compounds based on their predicted biological activities or interactions with specific targets like kinases or receptors involved in disease processes related our understanding about how drugs work at molecular level our ability predict how different modifications affect potency selectivity improve overall drug-like properties molecule.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)